Table 3.
Comparison of sensory attributes and patient preferences among INCS products
| Study | Design | Patients | INCS products | Results |
|---|---|---|---|---|
| Yonezaki et al (2016)38 | R, CO, MC | 40 adults with SAR | FF vs MF, each for 2 weeks | FF preferred in terms of less bitter taste (P=0.01), throat rundown (P=0.033), nose runout (P=0.002); FF induced less nasal irritation (P=0.012), sneezing (P=0.017), rhinorrhea (P=0.007); overall preference: FF by 52.5%, MF by 22.5%, no difference by 25% |
| Meltzer et al (2010)39 | R, DB, PC | 360 adults with SAR | FF vs FP, each for 7 days | FF preferred by more patients in terms of scent/odor (58 vs 27%), less throat rundown/nose runout (59 vs 21%), gentleness of nasal mist (57 vs 26%), and less aftertaste (60 vs 18%) (all P<0.001) |
| Khanna and Shah (2005)40 | R, CO | 114 adults with AR | MF vs FP vs BDP vs BUD single dose on 1 day | FP had strongest odor (P<0.05); MF caused least irritation, had least aftertaste, and had highest sensation of moistness (all P<0.05); overall preference: MF > BUD > FP ≥ BDP |
| Meltzer et al (2005)41 | R, DB, CO, MC | 100 adults with symptomatic AR | MF vs FP single dose on 1 day | MF preferred in terms of less scent/odor, immediate taste, aftertaste (all P<0.002) and nose runout (P<0.05); overall preference: MF by 53% and FP by 34% |
| Stokes et al (2004)42 | R, DB, CO (pooled from two studies) | 215 adults with symptomatic AR | TAA vs MF vs FP single dose on 1 day | TAA preferred in terms of least odor (P<0.001), least moistness in nose/throat (P<0.05), least aftertaste (P<0.05), and greatest overall liking (P<0.05); overall preference: TAA by 50%, FP by 25%, and MF by 25% |
| Shah et al (2003)43 | R, SB, CO, MC (two studies) | 371 adults with AR experiencing mild-to-moderate symptoms | BUD vs FP single dose on 1 day | BUD preferred in terms of less scent, taste, aftertaste, nose runoff/throat rundown in study 1 and in terms of less scent and taste in study 2 (all P<0.001); overall preference: BUD by 59% and FP by 41% in study 1 (P=0.021); BUD by 53.6% and FP by 46.4% in study 2 (not significant) |
| Lumry et al (2003)44 Bunnag et al (2003)45 | R, SB, PG, MC R, DB, CO, MC | 152 adults with SAR 364 adults with AR | TAA vs BDP for 3 weeks TAA vs FP vs MF single dose on 1 day | TAA preferred in terms of better taste and odor overall and at weeks 2 and 3 (P≤0.05) TAA preferred in terms of having lowest odor (P<0.0001), greatest comfort (P<0.05), and highest overall liking (P=0.0008); overall preference: TAA by 38.2%, FP by 36.8%, and MF by 24.9% |
| Bachert and El-Akkad (2002)46 | R, DB, CO, MC | 95 adults with AR | TAA vs FP vs MF single dose on 1 day | TAA preferred in terms of having lowest odor (P≤0.001), best taste (P≤0.01 TAA vs MF), and least aftertaste (P≤0.01), and causing least irritation (P≤0.05), but it caused the most nose runoff/throat rundown (P≤0.05); overall preference: TAA by 54.7%, MF by 24.2%, and FP by 21.1% |
Abbreviations: AR, allergic rhinitis; BDP, beclomethasone dipropionate; BUD, budesonide; CO, crossover; DB, double-blind; FF, fluticasone furoate; FP, fluticasone propionate; INCS, intranasal corticosteroids; MC, multicenter, MF, mometasone furoate; PC, placebo-controlled; PG, parallel group; R, randomized; SAR, seasonal allergic rhinitis; SB, single-blind; TAA, triamcinolone acetonide.